Geriatric Medicines

Global Geriatric Medicines Market to Reach US$222.5 Billion by 2030

The global market for Geriatric Medicines estimated at US$162.4 Billion in the year 2024, is expected to reach US$222.5 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Antihypertensive Therapeutics, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$49.9 Billion by the end of the analysis period. Growth in the Analgesics Therapeutics segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$43.8 Billion While China is Forecast to Grow at 8.9% CAGR

The Geriatric Medicines market in the U.S. is estimated at US$43.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$47.2 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Geriatric Medicines Market - Key Trends & Drivers Summarized

What Are Geriatric Medicines, and Why Are They Vital for an Aging Population?

Geriatric medicines are specialized drugs designed to address the unique health challenges faced by elderly patients. As people age, they often encounter multiple health issues, including chronic conditions like hypertension, diabetes, arthritis, and cognitive disorders, requiring a multidisciplinary approach to treatment. Geriatric medicines cater specifically to this demographic, focusing on conditions that are prevalent in older adults and providing therapies that are more appropriate for their physiological and metabolic needs. These medicines not only address disease management but also improve the overall quality of life for aging individuals by ensuring that treatment minimizes side effects and interactions with other medications. With the global population aging rapidly, especially in developed countries, the demand for geriatric medicines continues to grow, making it a crucial sector within the healthcare industry.

How Are Advances in Pharmaceuticals Shaping Geriatric Medicine Development?

Advances in pharmaceutical research and development are having a profound impact on the creation of more effective and safer geriatric medicines. One major area of innovation is the development of personalized medications that are tailored to the specific needs of elderly patients, taking into account their unique health conditions and the polypharmacy issues often associated with aging. Slow-release drug formulations, combination therapies, and easier-to-administer medications, such as patches and dissolvable tablets, are being developed to address compliance challenges that older adults face. Furthermore, biotechnology is playing a key role in creating targeted therapies for conditions such as Alzheimer’s, osteoporosis, and cardiovascular diseases, which are more prevalent in the geriatric population. These advancements not only improve treatment outcomes but also reduce the risk of drug interactions and side effects, ensuring that older adults can manage their conditions more effectively.

Why Are Changing Demographics and Healthcare Systems Driving Demand for Geriatric Medicines?

The aging global population is a significant driver of the demand for geriatric medicines. As life expectancy increases, the proportion of elderly individuals is growing rapidly, particularly in regions like North America, Europe, and East Asia. This demographic shift is creating an urgent need for healthcare systems to adapt and provide adequate medical care for older adults. Governments and healthcare providers are investing more in geriatric healthcare, with a focus on preventive care and the management of age-related chronic diseases. Additionally, as healthcare infrastructure improves in emerging markets, access to geriatric care is expanding, further fueling demand for specialized medicines. Public awareness of age-related health conditions is also increasing, leading to greater demand for early diagnosis and treatment options for conditions such as dementia, arthritis, and cardiovascular diseases. This growing focus on elderly care is transforming the healthcare landscape and making geriatric medicine a priority for healthcare providers and pharmaceutical companies alike.

What Is Driving the Growth of the Global Geriatric Medicines Market?

The growth in the global geriatric medicines market is driven by several factors, including advancements in drug development, an aging global population, and increased healthcare investment. One of the key growth drivers is the expanding elderly population, which is leading to a higher prevalence of chronic diseases that require long-term medical treatment. Pharmaceutical companies are responding by developing more targeted therapies and innovative drug delivery systems that cater to the specific needs of geriatric patients. Additionally, advancements in biotechnology and personalized medicine are opening new avenues for creating drugs that are more effective and have fewer side effects. The increasing focus on healthcare infrastructure improvements, especially in developing countries, is making geriatric medicines more accessible to a broader population. Furthermore, governments and healthcare organizations are placing a greater emphasis on preventive care and chronic disease management for the elderly, further driving the demand for specialized medicines. These factors, combined with growing public awareness of geriatric health issues, are contributing to the sustained growth of the global geriatric medicines market.

SCOPE OF STUDY:

The report analyzes the Geriatric Medicines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Therapeutic Type (Antihypertensive Therapeutics, Analgesics Therapeutics, Antidiabetic Therapeutics, Anticoagulant Therapeutics, Statins Therapeutics, Proton Pump Inhibitors Therapeutics, Antipsychotic Therapeutics, Other Therapeutic Types); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 52 Featured) -

• AbbVie, Inc.
• Adare Pharma Solutions
• Akums Drugs & Pharmaceuticals Ltd.
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Endo Pharmaceuticals, Inc.
• Ferring International Center SA
• Fortis Healthcare Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.